Pulmatrix closed at $1.52 on Nov 4, up 14.29%, 68.9% below its 52-week closing high. Volume of 218.8K shares was 8.80× its 20-day average (well above normal).
Split-adjusted performance: +6.3% over one month, +11.8% over six months.
Short interest was 43.2K shares at the Oct 15 settlement, down 11.8% from the prior report (1.2% of float, 2.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PULMPulmatrix | $1.52 | +14.29% | +11.8% | — | — | — | $5.6M | |
| SCNXScienture Holdings | $3.42 | −0.87% | −65.0% | — | −821.3% | — | $5.6M | Compare |
| ACXPAcurx Pharmaceuticals | $1.03 | +0.98% | −50.7% | — | — | — | $5.6M | Compare |
| LGVNLongeveron | $1.78 | 0.00% | −79.6% | −9.2% | −2116.0% | — | $5.7M | Compare |
| PCSAProcessa Pharmaceuticals | $1.94 | −0.26% | −29.6% | — | — | — | $5.4M | Compare |
| IMNNImunon | $0.9070 | +0.78% | −66.5% | — | — | — | $5.1M | Compare |
| SKYESkye Bioscience | $1.14 | −6.56% | −83.3% | — | — | — | $5.0M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
| CNSPCNS Pharmaceuticals | $4.34 | −4.62% | −37.1% | — | — | — | $6.3M | Compare |
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
